Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.1.4-1 | Award Amount: 7.85M | Year: 2013
The discrepancy between organ supply and demand remains the biggest challenge facing the transplant community today. In order to increase the amount of available donor organs, transplant specialists are increasingly turning to sub-optimal donor organs. Organs from such donors, usually have normal or near normal function before death, but retrieval, storage and transplantation cause progressive injury to the organ. Injury is predominantly caused by inadequate or absent delivery of oxygen and nutrients, either in the warm or cold preservation environment. New techniques to improve organ preservation are being developed and the COPE consortium including: Normothermic liver machine perfusion (NMP) Hypothermic kidney machine perfusion (HMP) Novel additives for preservation solutions These strategies are all directed to the vital period that starts at the time of circulatory arrest and extends to the point of transplantation. Specifically, they will tackle the following challenges: Exposure of donor organs to ischaemic injury whilst the organs remain in the donor. Progressive deterioration of the organ during conventional organ preservation. Repair of the organ during preservation using perfusate and pharmacological interventions. Identification of reliable predictors of organ viability using biological and other pre-transplant parameters. The COPE consortium is the official organ preservation task force of ESOT and consists of a number of European transplantation centers, front running transplantation research groups and a number of SMEs involved in developing perfusion fluids and technology. Together, they will be able to generate the statistical power and protocols necessary to test, validate and promote these new organ preservation techniques and increase the number of available solid donor organs.
French National Center for Scientific Research, Hemarina, University Pierre and Marie Curie | Date: 2015-12-15
The invention relates to the use of a haemoglobin for the preparation of dressings and to the resulting dressings.
Hemarina | Date: 2014-05-14
The invention relates to a lyophilisate or to a powder including i) at least one globin, a globin protomer or an extracellular hemoglobin from annelids, and ii) at least one biological material from annelids that is different from said globin, from said protomer and from said hemoglobin.
Hemarina | Date: 2010-05-07
The present invention relates to isolated haemoglobin from worms belonging to the Nereididae family and its use in cell culture medium, in preservation solutions and as artificial oxygen carrier for transfusion.
Hemarina | Date: 2012-08-23
A method for maintaining stem cells in the undifferentiated state by mixing the stem cells with at least one extracellular hemoglobin, globin or globin protomer from annelids.
Hemarina | Date: 2014-02-14
A method for treating cancer using at least one globin, a globin protomer or an extracellular haemoglobin of annelids.
Hemarina | Date: 2013-06-05
The present invention relates to a lyophilizate comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. The present invention also relates to a composition comprising: a solution comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. Finally, the present invention relates to a process for preparing the lyophilizate.
Hemarina | Date: 2012-05-30
The invention relates to the use of a composition comprising at least one globin, one globin protomer or one extracellular hemoglobin of Annelida, a stabilizing solution and/or a solution for conserving organs, said composition having a temperature of between 0 C. and 37 C., for preserving an organ in a donation after brain death donor or a donation after cardiac death donor. The invention also relates to a method for conserving an organ in situ in a donation after brain death donor or a donation after cardiac death donor using normothermic ECMO or double-balloon triple-lumen catheter techniques or any other similar technique.
Hemarina | Date: 2010-04-21
The present invention relates to devices and bioreactors capable of delivering oxygen to a cell culture using oxygen-carrying molecules. The bioreactor comprises at least two chambers separated by an oxygen-permeable membrane. The oxygen-carrying molecules are chosen from extracellular hemoglobin isolated from worm belonging to Arenicoliolae family or Nereidiolae family.
Hemarina | Date: 2015-09-30
The present invention relates to a composition comprising a respiratory pigment chosen from marine chlorocruorins, marine hemerythrins and marine hemocyanins, and a mixture of sodium chloride, calcium chloride, magnesium chloride or sulfate, potassium chloride, sodium gluconate and sodium acetate, for use as a blood substitute.